Mitogen-activated protein kinase–activated protein kinase 2 (MK2)

Mitogen‑activated protein kinase–activated protein kinase 2 (MK2) is a serine/threonine-protein kinase encoded by the MAPKAPK2 gene in humans. It acts downstream of the p38 mitogen‑activated protein kinases within cellular stress-response pathways. Upon activation through direct phosphorylation by p38 MAPKs, MK2 regulates diverse biological processes including inflammation, cell proliferation/division, apoptosis/cell death decisions, cytoskeletal remodeling/migration, nuclear export mechanisms, gene expression regulation at both transcriptional and translational levels—including stabilization/translation control for key inflammatory cytokines—and maintenance of genomic stability via cell cycle checkpoints. Its major substrates include heat shock proteins such as Hsp27 whose phosphorylation state can serve both functional roles in chaperone biology and as biomarkers for disease progression or therapeutic efficacy monitoring. Due to its central role in mediating pathological inflammation without some liabilities seen with broader pathway inhibition (e.g., direct p38 blockade), it has emerged as an attractive drug target for diseases ranging from autoimmune/inflammatory disorders to certain cancers and cardiovascular conditions like pulmonary hypertension.

Other names

MK2MAPKAPK2Mitogen-activated protein kinase activated protein kinase 2Stress-activated serine/threonine-protein kinase

Drugs targeting this molecule typically act as ATP-site competitive inhibitors of the serine/threonine-protein kinase activity of MK2 or indirectly inhibit its activation by blocking upstream kinases such as p38 MAPK. The goal is to reduce inflammatory cytokines' mRNA stability/translation or modulate stress responses in disease contexts like cancer or cardiovascular disease.